Use of nonhuman primate models to develop mucosal AIDS vaccines

Meritxell Genescà, Chris J Miller

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 trial were designed to elicit strong systemic immune responses; therefore, strategies to direct immune responses into mucosal sites should be tested in an effort to improve AIDS vaccine efficacy. However, as increased CD4 + T-cell activation and recruitment to mucosal sites have the potential to enhance HIV transmission, mucosal immune responses to HIV vaccines should primarily consist of effector CD8 + T cells and plasma cells. Controlling the level of mucosal T-cell activation may be a critical factor in developing an effective mucosal AIDS vaccine. Immunization routes and adjuvants that can boost antiviral immunity in mucosal surfaces offer a reasonable opportunity to improve AIDS vaccine efficacy. Nonhuman primate models offer the best system for preclinical evaluation of these approaches.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalCurrent HIV/AIDS Reports
Issue number1
StatePublished - Feb 2010


  • Female genital tract
  • HIV
  • Immune activation
  • SIV

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases


Dive into the research topics of 'Use of nonhuman primate models to develop mucosal AIDS vaccines'. Together they form a unique fingerprint.

Cite this